Daniel A. Ermann, MD, on First-Line Therapy for CLL: Real-World Outcomes Among Medicare Beneficiaries
ASCO 2026
Daniel A. Ermann, MD, of Huntsman Cancer Institute, University of Utah School of Medicine, presents findings from a retrospective cohort study which used a large U.S. database to evaluate clinical outcomes among Medicare beneficiaries treated with first-line therapy for chronic lymphocytic leukemia (CLL) (Abstract 7047).
To learn more about this data, read a related article in Oncology and Therapy.
The ASCO Post Staff
Mary-Ellen Taplin, MD, FASCO, of Dana-Farber Cancer Institute, presents the final analysis of the phase III PROTEUS study, which looked at perioperative (neoadjuvant and adjuvant) apalutamide plus androgen-deprivation therapy (ADT) vs placebo and ADT with radical prostatectomy in patients with high-risk localized or locally advanced prostate cancer (Abstract LBA1).
The ASCO Post Staff
Supriya Gupta, MD, of the University of Minnesota, presents data on azercabtagene zapreleucel, an investigational anti-CD19 allogeneic chimeric antigen receptor (CAR) T-cell therapy, in combination with low-dose interleukin-2 in patients with relapsed or refractory non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) (Abstract 7012).
Dor Abelman, BS, of the University of Toronto, reviews results of a comparison of two minimally invasive measurable residual disease (MRD) assays—BM-informed cfDNA whole-genome sequencing (cfWGS) and plasma proteomic MRD (EasyM)—in patients with multiple myeloma (Abstract 7546).
Gopa Iyer, MD, of Memorial Sloan Kettering Cancer Center, presents initial results from the phase I NEXUS-01 study, which evaluated LY4052031, an antibody-drug conjugate targeting Nectin-4, in patients with advanced or metastatic urothelial carcinoma (Abstract 4508).
The ASCO Post Staff
Tony S.K. Mok, MD, FRCPC, FASCO, of the Chinese University of Hong Kong, presents long-term findings from the CROWN trial, which evaluated lorlatinib vs crizotinib in patients with advanced ALK-positive non–small cell lung cancer (NSCLC). At 5 years, median progression-free survival was not reached with lorlatinib in this population, representing the longest progression-free survival ever reported in advanced NSCLC (Abstract 8502).
